Prostate gland volume is a strong predictor of biopsy results in men 70 years or older with prostate-specific antigen levels of 2.0-10.0 ng/mL

International Journal of Urology

Volumn 12, Issue 11, 2005, Pages 969-975

  Kobayashi, Takashi ^a   Mitsumori, Kenji ^a   Kawahara, Takashi ^a   Nishizawa, Koji ^a   Ogura, Keiji ^a   Ide, Yoshihiro ^a  

^a HAMAMATSU ROSAI HOSPITAL   (Japan)

Author keywords

Older patient; Prostate biopsy; Prostate volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC;

AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; LOGISTIC MODELS; MALE; ORGAN SIZE; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ROC CURVE;

EID: 30944467220     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2005.01189.x     Document Type: Article

References (36)

1. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997; 277: 1452-5.
2. Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schroder FH. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J. Urol. 1997; 157: 2191-6.
3. Reissigl A, Klocker H, Pointner J, Ennemoser O, Falk M, Bartsch G. Improvement of prostate cancer screening by determination of the ratio free/total PSA in addition to PSA levels. Prostate 1997; 30: 243-7.
4. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol. 1992; 147: 817-21.
5. Catalona WJ, Richie JP, deKernion JB et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J. Urol. 1994; 152: 2031-6.
6. Gohji K, Nomi M, Egawa S et al. Detection of prostate carcinoma using prostate specific antigen, its density, and the density of the transition zone in Japanese men with intermediate serum prostate specific antigen concentrations. Cancer 1997; 79: 1969-76.
7. Zlotta AR, Djavan B, Marberger M, Schulman CC. Prostate specific antigen density of the transition zone: a new effective parameter for prostate cancer prediction. J. Urol. 1997; 157: 1315-21.
8. Catalona WJ, Bartsch G, Rittenhouse HG et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2-4 ng/ml. J. Urol. 2003; 170: 2181-5.
9. Saika T, Tsushima T, Nasu Y et al. Prostate specific antigen complexed to alpha-1-antichymotrypsin in patients with intermediate prostate specific antigen levels. Cancer 2002; 94: 1685-91.
10. Lein M, Kwiatkowski M, Semjonow A et al. A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J. Urol. 2003; 170: 1175-9.
11. Berger AP, Cheli C, Levine R, Klocker H, Bartsch G, Horninger W. Impact of age on complexed PSA levels in men with total PSA levels of up to 20 ng/mL. Urology 2003; 62: 840-4.
12. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J. Urol. 1997; 157: 199-202.
13. Babaian RJ, Toi A, Kamoi K et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J. Urol. 2000; 163: 152-7.
14. Presti JC Jr, Chang JJ, Bhargava V, Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J. Urol. 2000; 163: 163-6.
15. Richie JP, Catalona WJ, Ahmann FR et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993; 42: 365-74.
16. Terris MK, Stamey TA. Determination of prostate volume by transrectal ultrasound. J. Urol. 1991; 145: 984-7.
17. Terris MK, Wallen EM, Stamey TA. Comparison of mid-lobe versus lateral systematic sextant biopsies in the detection of prostate cancer. Urol. Int. 1997; 59: 239-42.
18. Presti JC Jr, O'Dowd GJ, Miller MC, Mattu R, Veltri RW. Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J. Urol. 2003; 169: 125-9.
19. Kobayashi T, Nishizawa K, Watanabe J, Ogura K, Mitsumori K, Ide Y. Effects of sextant transrectal prostate biopsy plus additional far lateral cores in improving cancer detection rates in men with large prostate glands. Int. J. Urol. 2004; 11: 392-6.
20. Fleshner NE, Fair WR. Indications for transition zone biopsy in the detection of prostatic carcinoma. J. Urol. 1997; 157: 556-8.
21. Durkan GC, Sheikh N, Johnson P, Hildreth AJ, Greene DR. Improving prostate cancer detection with an extended-core transrectal ultrasonography- guided prostate biopsy protocol. BJU Int. 2002; 89: 33-9.
22. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J. Urol. 2001; 166: 104-109.
23. Schwartz KL, Alibhai SM, Tomlinson G, Naglie G, Krahn MD. Continued undertreatment of older men with localized prostate cancer. Urology 2003; 62: 860-5.
24. Yan Y, Carvalhal GF, Catalona WJ, Young JD. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 2000; 88: 1122-30.
25. Bubolz T, Wasson JH, Lu-Yao G, Barry MJ. Treatments for prostate cancer in older men: 1984-1997. Urology 2001; 58: 977-82.
26. Moul JW, Wu H, Sun L et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national data-base. Surgery 2002; 132: 213-19.
27. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for prostate-specific antigen in black men. N. Engl. J. Med. 1996; 335: 304-10.
28. Ung JO, San Francisco IF, Regan MM, DeWolf WC, Olumi AF. The relationship of prostate gland volume to extended needle biopsy on prostate cancer detection. J. Urol. 2003; 169: 130-5.
29. Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughan ED Jr. The influence of prostate size on cancer detection. Urology 1995; 46: 831-6.
30. Basillote JB, Armenakas NA, Hochberg DA, Fracchia JA. Influence of prostate volume in the detection of prostate cancer. Urology 2003; 61: 167-71.
31. Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J. Urol. 2000; 164: 388-92.
32. Oesterling JE, Jacobsen SJ, Chute CG et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860-4.
33. Oesterling JE, Kumamoto Y, Tsukamoto T et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br. J. Urol. 1995; 75: 347-53.
34. Tsukamoto T, Kumamoto Y, Masumori N et al. Prevalence of prostatism in Japanese men in a community-based study with comparison to a similar American study. J. Urol. 1995; 154: 391-5.
35. Rodriguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy, a prospective study and review of the literature. J. Urol. 1998; 160: 2115-20.
36. Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology 2002; 60: 826-30.